Journey Medical Co. (NASDAQ:DERM) Short Interest Update

Journey Medical Co. (NASDAQ:DERM) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 76,800 shares, a growth of 14.8% from the December 15th total of 66,900 shares. Based on an average daily volume of 108,900 shares, the short-interest ratio is currently 0.7 days. Approximately 0.8% of the company’s shares are short sold.

Institutional Investors Weigh In On Journey Medical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DERM. PVG Asset Management Corp grew its holdings in Journey Medical by 5.7% in the 3rd quarter. PVG Asset Management Corp now owns 167,545 shares of the company’s stock worth $947,000 after acquiring an additional 9,005 shares during the last quarter. Nwam LLC purchased a new stake in shares of Journey Medical during the third quarter worth about $59,000. Kovitz Investment Group Partners LLC purchased a new stake in shares of Journey Medical during the third quarter worth about $66,000. Geode Capital Management LLC grew its position in shares of Journey Medical by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock worth $613,000 after buying an additional 12,882 shares during the last quarter. Finally, ORG Wealth Partners LLC bought a new position in shares of Journey Medical during the third quarter valued at approximately $110,000. 7.25% of the stock is currently owned by institutional investors.

Journey Medical Trading Down 3.4 %

DERM stock traded down $0.13 during midday trading on Friday, hitting $3.66. The company had a trading volume of 51,888 shares, compared to its average volume of 55,888. The stock has a market cap of $76.46 million, a price-to-earnings ratio of -3.89 and a beta of 1.00. Journey Medical has a 52 week low of $2.85 and a 52 week high of $6.89. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 1.81. The stock’s 50 day moving average price is $4.79 and its 200 day moving average price is $5.18.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.